ReviewCurrent medicinal chemistry2021
Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development.
Review in Current medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 4 syntheses or guidelines pooled it, 216 citations in OpenAlex.
- Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function.Frontiers in pharmacology · 2025Pooled it
- Proteomic Biomarkers Associated with Low Bone Mineral Density: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Using a Polygenic Score to Predict the Risk of Developing Primary Osteoporosis.International journal of molecular sciences · 2022Pooled it
- Is diabetes mellitus a risk factor for low bone density: a systematic review and meta-analysis.BMC endocrine disorders · 2021Pooled it
- Pro-Osteogenic Effect of the Nutraceutical BlastiMin ComplexInternational journal of molecular sciences · 2024Trial
- Baicalein Attenuates Disuse-Driven Skeletal Senescence in Association with Gut Microbiota Modulation.Molecules (Basel, Switzerland) · 2026Article
- Artificial Intelligence-Assisted Structural Analysis of Bones with Paget's Disease of Bone and Osteoporosis: Lessons from Mouse Models.Diagnostics (Basel, Switzerland) · 2026Article
- The Early Effect of Alendronate, Hop Extract and Their Combination on Bone Structural Properties in a Rat Model of Osteoporosis.Medical sciences (Basel, Switzerland) · 2026Article
- Integrated network pharmacology and pharmacological evaluation to elucidate the effect and mechanism of the novel combination PMS in treatment of osteoporosis.Journal of natural medicines · 2026Article
- Modulation of Intestinal-Bone Crosstalk by a Standardised Nutraceutical Combination: An In Vitro Mechanistic Study.Nutrients · 2026Article
- The orally available SIK2/SIK3 inhibitor SK-124 increases bone mass in hypogonadal male mice.JBMR plus · 2026Article
- Myocyte-Specific Enhancer Factor 2A Potentiates Osteoclastic Differentiation in Osteoporosis by Inducing Endothelin Receptor Type A.Biochemical genetics · 2026Article
- METTL14 mitigates osteoporosis progression by promoting osteogenic differentiation of BMMSCs through improving mitochondrial dysfunction.Journal of molecular histology · 2026Article
- MECP2 Insufficiency Attenuates RUNX2-Dependent Osteoblast Differentiation via miR-126-3p/DKK1-Mediated Canonical Wnt Signaling Inhibition in Rett Syndrome.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Tocotrienol-Incorporated Gelatin Hydrogel Crosslinked with Genipin for Future Bone Tissue Engineering Applications: Physiochemical Characterization and Biocompatibility.International journal of molecular sciences · 2026Article
- Review
- Branched‑chain amino acid metabolism and bone metabolism: Implications for osteoporosis pathogenesis and therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Apoptosis-related genes bridge inflammatory bowel disease and osteoporosis: A bioinformatic analysis.PloS one · 2026Article
- To evaluate the value of L1 cortical bone quantitative CT parameters in predicting osteoporosis.Frontiers in medicine · 2026Article
- 5-methoxyresorcinol mitigates postmenopausal osteoporosis through regulation of the PI3K-AKT-GSK3β signaling pathway and ROS homeostasis.Frontiers in pharmacology · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
CDATA[Osteoporosis is a pathological loss of bone mass due to an imbalance in bone remodeling where osteoclast-mediated bone resorption exceeds osteoblast-mediated bone formation resulting in skeletal fragility and fractures. Anti-resorptive agents, such as bisphosphonates and SERMs, and anabolic drugs that stimulate bone formation, including PTH analogues and sclerostin inhibitors, are current treatments for osteoporosis. Despite their efficacy, severe side effects and loss of potency may limit the long term usage of a single drug. Sequential and combinational use of current drugs, such as switching from an anabolic to an anti-resorptive agent, may provide an alternative approach. Moreover, there are novel drugs being developed against emerging new targets such as Cathepsin K and 17β-HSD2 that may have less side effects. This review will summarize the molecular mechanisms of osteoporosis, current drugs for osteoporosis treatment, and new drug development strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.